Anzeige
Mehr »
Login
Mittwoch, 29.01.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14Z7X ISIN: CA00444G1081 Ticker-Symbol: 3TP 
Frankfurt
28.01.20
08:00 Uhr
0,050  Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ACERUS PHARMACEUTICALS CORPORATION Chart 1 Jahr
5-Tage-Chart
ACERUS PHARMACEUTICALS CORPORATION 5-Tage-Chart

Aktuelle News zur ACERUS PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ACERUS PHARMACEUTICALS Aktie jetzt für 4€ handeln
DiAcerus Pharmaceuticals Corp: Acerus's Natesto abstract to be presented at meeting-
10.01.Acerus Pharmaceuticals Corp: Acerus to complete more studies re Natesto6
18.12.19Acerus Pharmaceuticals Corp: Acerus closes amendment, restatement of $5M (U.S.) loan2
16.12.19Acerus Pharmaceuticals Corp: Acerus amends SWK credit facility-
02.12.19Acerus Pharmaceuticals Corp: Acerus completes revised Natesto partner deal with Aytu-
02.12.19Aytu Bio launches Natesto U.S. co-promotion with Acerus Pharma2
02.12.19Aytu BioScience, Inc.: Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals827Acerus Launches U.S. Specialty Sales Force; Sales Team Expansion Nearly Doubles Current Natesto Sales Force Expanded Commercial Operations Expected to Accelerate Natesto Growth in the U.S. ENGLEWOOD...
► Artikel lesen
14.11.19Acerus Pharmaceuticals Corp: Acerus Pharmaceuticals loses $4.61M (U.S.) in Q3 20191
01.11.19Acerus Pharmaceuticals Corp: Acerus alters Natesto, to submit SNDS to Health Canada3
17.10.19Acerus Pharmaceuticals Corp: Acerus talks up Natesto spermatogenesis study results1
30.09.19Acerus Pharmaceuticals Corp: Acerus amends credit facility with SWK Funding-
08.08.19Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2019 Results - Earnings Call Transcript-
07.08.19Acerus Pharmaceuticals Corp: Acerus Pharmaceuticals loses $3.2M (U.S.) in Q2-
02.08.19Acerus Pharmaceuticals Corp: Acerus to replace some "non-conforming" Natesto lots1
30.07.19Aytu BioScience, Inc.: Aytu BioScience Expands Natesto(R) Partnership with Acerus Pharmaceuticals to Accelerate Natesto Growth in the U.S.103Acerus to Launch U.S. Specialty Sales Force; Nearly Doubles Natesto Sales Force ENGLEWOOD, CO / ACCESSWIRE / July 30, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1